29th August, 2026
To,
The General Manager
BSE Limited,
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in relation to the allotment of 31,37,586 equity shares and 21,45,145 convertible warrants on a preferential basis.

Ref: Intimation dated 02nd July, 2026 and disclosure dated 22nd August, 2026 issued by Parmax Pharma Limited (the "Company").

Dear Sir/ Mam,

We refer to the above-mentioned intimation and disclosure made by the Company in connection with the preferential issue of: (i) 31,37,586 equity shares; and (ii) 21,45,145 convertible warrants., we hereby inform you that the Board of directors of the Company, at their meeting held on today, i.e. 29th August inter alia, approved the following:

1. Allotment of 31,37,586 fully paid-up equity shares of the Company at face value of Rs.10 - (Rupee ten only) each to the members of the non-promoter category, on a preferential basis.
2. Allotment of 21,45,145 convertible warrants by way of a preferential issue on a private placement basis to a person belonging to the non-promoter category, convertible into one equity share of fully paid equity shares of the Company having face value of Rs.10/- (Rupees ten only) each, in one or more tranches within a period of 18 months from the date of allotment of convertible warrants.

The Company has received the in-principal approval from the Stock Exchange on 21st August, 2026, for issue of the aforesaid specified securities on preferential basis.

The meeting of the Board commenced at 3.30 p.m. and concluded at 4.00 p.m.

Brief details in accordance with Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure I & Annexure II.

The above information is also available on the website of the company at www.parmaxpharma.com

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For Parmax Pharma Limited

UMANG ALKESH GOSALIA

Digitally signed by UMANG ALKESH GOSALIA
Date: 2026.08.29 16:15:09 +05'30'

Umang Gosalia
Managing Director
DIN: 05153830

Encl. Annexure I & II

ANNEXURE: I

Disclosure in terms of Regulation 30 of the Listing Regulations, read with SEBI Circular on Preferential Issue

S.no.	Particulars	Details
1.	Type of securities proposed to be issued (viz., equity shares, convertibles, etc.)	Fully paid-up equity shares of the Company.
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment, etc.)	Preferential allotment
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	The Company allotted 31,37,586 (Thirty one lakh thirty seven thousand five hundred and eighty six) fully paid-up equity shares having a face value of Rs. 10/- each at an issue price of ₹36.50 (Rupees Thirty six point five zero) per Subscription Share which includes a premium of ₹ 26.50 (Rupees Twenty-six point five zero) per equity share aggregating to Rs. 11,45,21,889 (Rupees Eleven Crore Forty-Five Lakh Twenty-One Thousand Eight Hundred Eighty-Nine crores only) to the Non-Promoter Group Category. The Equity shares allotted shall rank pari-passu with the existing equity shares of the Company.
4.	**Additional Information in case of Preferential Issue:**	
a.	Name of the Proposed Allottees	List Enclosed as Annexure-1 A
b.	Post allotment of securities - outcome of the subscription	
c.	Issue Price ~~/ allotted price (in case of convertibles),~~	₹ 36.50 (Rupees Thirty six point five zero) per Subscription Share which includes a premium of ₹ 26.50 (Rupees Twenty-six point five zero) per equity share
d.	Number of Proposed Allottees	14 (Fourteen)
e.	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Not Applicable
5.	Any cancellation or termination of the proposal for the issuance of securities including reasons thereof.	Not Applicable

ANNEXURE: II

Disclosure in terms of Regulation 30 of the Listing Regulations, read with SEBI Circular on Preferential Issue

S.no.	Particulars	Details
1.	Type of securities proposed to be issued (viz., equity shares, convertibles, etc.)	Fully Convertible warrants each convertible into an equivalent number of fully paid-up equity shares of the Company.
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment, etc.)	Preferential allotment
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	21,45,145 (Twenty one lakhs forty five thousand one hundred and forty five) warrants, convertible into an equivalent number of fully paid-up equity shares having a face value of Rs. 10/- each at a price of Rs. 36.50/- per warrant to Non-Promoter Category.
4.	**Additional Information in case of Preferential Warrants Issue:**	
a.	Name of the Proposed Warrants Allottees	List Enclosed as Annexure-1 A
b.	Post allotment of securities - outcome of the subscription	
c.	Issue price / allotted price (in case of convertibles),	₹ 36.50 (Rupees Thirty-six point five zero) which includes a premium of ₹ 26.50 (Rupees Twenty-six point five zero) per warrant (i.e. warrant exercise price), as per the provisions of Regulation 164 of Chapter V of the SEBI ICDR Regulations.
d.	Number of Proposed Warrants Allottees	13 (Thirteen)
e.	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Each warrant will be convertible into 1 equity share of Rs. 10/- each and the rights attached to the warrants can be exercised in one or more tranches at any time within the period of 18 (eighteen) months from the date of allotment of the warrants, subject to other terms and conditions as applicable. The Equity shares to be allotted upon conversion of warrants shall rank pari passu with the existing equity shares of the Company.
5.	Any cancellation or termination of the proposal for the issuance of securities including reasons thereof.	Not Applicable

List Enclosed as Annexure-1 A

Sr. No.	Name of the Allottees/ Warrants Allottees	Current Status / Category	Proposed status / Category of the Allottees	Pre-Issue Holding (No. of Equity Shares) (A)	% of Pre Preferential Issue Capital (% of A) 2026 (B)	No. of Equity Shares / Subscription Shares allotted (C)	No. of Warrants allotted (D)	Post-Issue Holding (No. of Equity Shares) (E)*^	% of Post Preferential Issue of Equity Shares (% of E)
1.	Dhiren Chandulal Shah	Non-Promoter (Public)	Promoter	0.00	0.00	604,190	535,715	11,39,905	12.63
2.	Sunil Chinubhai Shah	Non-Promoter (Public)	Promoter	0.00	0.00	91,911	81,494	1,73,405	1.92
3.	Hiren Pravin Doshi	Non-Promoter (Public)	Promoter	0.00	0.00	217,508	192,857	410,365	4.55
4.	Umang Alkesh Gosalia	Non-Promoter (Public)	Promoter	200,000	5.35	342,466	--	542,466	6.01
5.	Sheetal Hiren Doshi	Non-Promoter (Public)	Promoter Group	0.00	0.00	24,167	21,429	45,596	0.51
6.	Nirmal Sunilbhai Shah	Non-Promoter (Public)	Promoter Group	32,500	0.87	164,832	144,715	342,047	3.79
7.	Dhairya Dhiren Shah	Non-Promoter (Public)	Promoter Group	0.00	0.00	120,838	107,143	227,981	2.53
8.	Rupa Sunil Shah	Non-Promoter (Public)	Promoter Group	0.00	0.00	69,206	61,363	130,569	1.45
9.	Vijaykumar Natvarlal Shiyani	Non-Promoter (Public)	Promoter Group	0.00	0.00	161,117	142,857	303,974	3.37
10.	Kamlesh Natvarlal Shiyani	Non-Promoter (Public)	Promoter Group	7,500	0.20	161,974	143,286	312,760	3.47
11.	Abhay Chinubhai Shah	Non-Promoter (Public)	Promoter Group	0.00	0.00	322,235	285,715	607,950	6.74
12.	Urvi Manish Kothari	Non-Promoter (Public)	Non-Promoter (Public)	0.00	0.00	285,714	142,857	428,571	4.75
13.	Mili Saumil Shah	Non-Promoter (Public)	Non-Promoter (Public)	0.00	0.00	285,714	142,857	428,571	4.75
14.	Fredun Nariman Medhora	Non-Promoter (Public)	Non-Promoter (Public)	0.00	0.00	285,714	142,857	428,571	4.75

Note: % of holding of the equity shares allotted are calculated based on post-preferential shareholding assuming allotment of 31,37,586 Equity Shares and conversion 21,45,145 Warrants to Equity Shares (assuming full conversion).

** The above shareholding details of the Allottees/ Warrants Allottees in the Company, only represents the shareholding before and after the Preferential Allotment.*